undamentalytics Newsletter
Sign in

Septerna, Inc. (SEPN) stock

Add to watchlist

Add holding +

NASDAQ: SEPN Nasdaq Biotechnology Next results ~November 9, 2026

A Fundamentals grade

Septerna, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$26

Cash-flow model

Base case. Range ~$22–$32 across our lower- and higher-growth cases (8%–18% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 39% below it.

Price used: $43.20, November 2, 2026

Septerna, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 28 sales by directors and officers, last 12 monthsInsider trades
  • Funds95 adding, 48 cuttingOf 39 active managers that changed their stake, 26 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Septerna files

Where Septerna stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $99m, up 13520.1% on a year earlier, faster than the 7295.6% growth a quarter earlier. That growth ranks 3 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to 106.3% from -11436.9% a year earlier. Operating margin widened to -44.0% from -14071.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades A. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $33.91 a share.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Septerna, Inc.'s trailing-twelve-month revenue grew 13520.1% year on year, with a free-cash-flow margin of 106.3%. Where it stands out: free-cash-flow margin of 106.3% ranks 1 of 176 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$26 per share in the base case (~$22–$32 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to 13520.1% (+6224.5pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 13520.1% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 6224.5 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 14027.0 points on a year ago.
  • Strong cash generation. 106.3% of revenue turned into free cash flow, against a median of -145.4% for biotechnology companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Priced above our value. The share price of $43.20 is 56% above our value per share of $19.
  • Loss-making. Operating margin is -44.0%: costs exceed revenue.
  • Heavy stock-based pay. Stock pay equals 16.5% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • High sales multiple. The shares trade at 20 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 67% and a beta of 1.0 against the S&P 500.

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$0.29 against an average estimate of -$0.49: beat by 41.2%
Revenue
$27m, up 22375.6% on a year earlier
Share reaction
+23.0% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.40

Septerna's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.8%
  • 1 week+4.4%
  • 1 month+14.6%
  • This year+54.9%
  • 1 year+109.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$98.9M
Operating margin
-44.0%
Net margin
-24.5%
EPS (TTM, diluted)
$-0.54

Growth

Revenue growth
+13520.1%
Change in growth rate
+6224.5 pts

Cash

Free cash flow (TTM)
$105M
FCF margin
106.3%
Stock pay % of revenue
16.5%

Earnings

Last results
August 10, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Septerna, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 22.4% a year of cash-flow growth for five years.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in22.4%
  • Last 12 months13520.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($44.20, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$19
Price used
$44.20close November 3, 2026
Implied change
▼ 57%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Septerna, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($32M, FY2026 Q2 TTM), growing -8.2% and -4.8% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$16–~$23 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Septerna, Inc.'s free cash flow after stock-based pay ( $32M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Septerna, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$26 ~$22–$32 Primary model, counts double
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.5 ~$8.7–$9.9 Included
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$21 ~$9.5–$26 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Septerna, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −22%
  • Revenue growth 5 points higher ▲ +28%
  • Free-cash-flow margin 1 point lower ▼ −1%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $18$22$27$33$41$52
8.5% $16$19$22$27$32$40
10% $14$16$19$23$27$33

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$22.90$27.88$43.20
Market value$227m$1.2bn$1.9bn
+ Net debt (− = net cash)−$238m−$121m−$85m
Enterprise value−$12m$1.1bn$1.8bn
Multiples
Price / sales n/m26.9x19.5x
Price / earnings ———
Price / free cash flow —11.3x18.4x
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $21m and EPS of −$0.40 (range −$0.69 to −$0.24) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.19 +14% $96m +109%
Next −$1.94 −64% $74m −23%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −35.5% on 90 days ago. In the last 30 days, 2 analysts raised Septerna, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Septerna, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.84 Current fiscal year, 60 days ago: −$1.84 Current fiscal year, 30 days ago: −$1.18 Current fiscal year, 7 days ago: −$1.19 Current fiscal year, Now: −$1.19 −$1.19 Next fiscal year, 90 days ago: −$2.66 Next fiscal year, 60 days ago: −$2.66 Next fiscal year, 30 days ago: −$1.83 Next fiscal year, 7 days ago: −$1.94 Next fiscal year, Now: −$1.94 −$1.94

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.84−$2.66
60 days ago −$1.84−$2.66
30 days ago −$1.18−$1.83
7 days ago −$1.19−$1.94
Now −$1.19−$1.94

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.49 −$0.29 +41.2%
Mar 2026 −$0.27 −$0.19 +30.8%
Dec 2025 −$0.22 −$0.24 −8.5%
Sept 2025 $0.79 −$0.10 −112.3%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Septerna, Inc.'s revenue by -4.0% next year and +3.3% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (-14.2%, weight 62%) and the company's own record (+13.0%, weight 38%) . How the weights are set.

Analyst recommendations

10 analysts, Oct 2026
Buy10100%
Hold00%
Sell00%

Monthly trend

  1. Oct 20261910
  2. Sep 20261910
  3. Aug 20261910

Counts of recommendations published by analysts covering Septerna, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.4%
of tradable shares
Days to cover
8.65
at average volume
Short interest, 1 month
+22%
to October 15, 2026
Held by institutions
99%
of shares
Held by insiders
2.9%
of shares
Employees
123
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 20252026 to date
Return
SEPN+22%+55%
Industry peers (median)−5%−27%
S&P 500+18%+11%
Months that ended higher
SEPN58%64%
S&P 50075%46%
Largest fall from a high during the year
SEPN−79%−26%
S&P 500−19%−9%

Worst fall since October 25, 2024: 82% from December 23, 2024 to April 1, 2025. Getting back needed a 440% gain, reached on November 24, 2025, 237 days after the low.

Price behaviour

52-week range
$18.10 – $48.19
From 52-week high
−10.4%
vs 50-day average
+10.7%
vs 200-day average
+34.3%
Volatility (1 year)
67%
Beta vs S&P 500
1.02

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 5 down
typical move ±6.5%
After a week
4 up, 4 down
typical move ±8.6%
After a month
6 up, 2 down
typical move ±15.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 +23.0% −0.3% +13.8% −2.2%
May 11, 2026 +4.1% +0.1% +10.2% +27.6%
March 9, 2026 −2.6% +0.7% −12.6% −14.9%
November 10, 2025 +3.9% +1.8% +16.9% +38.5%
August 11, 2025 −4.2% +0.9% −0.9% +25.9%
May 15, 2025 −3.1% +1.1% −6.7% +3.7%
March 27, 2025 −0.7% −2.3% −5.5% +14.0%
November 20, 2024 −10.0% +0.6% +2.4% +0.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Septerna, Inc. in five measures

Fundamentals grade A
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Septerna, Inc.
$0 $50M $100M FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY24 Q2: $838K Revenue (TTM), FY24 Q3: $981K Revenue (TTM), FY24 Q4: $1.1M Revenue (TTM), FY25 Q1: $977K Revenue (TTM), FY25 Q2: $726K Revenue (TTM), FY25 Q3: $22M Revenue (TTM), FY25 Q4: $46M Revenue (TTM), FY26 Q1: $72.3M Revenue (TTM), FY26 Q2: $98.9M $98.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $838K
FY24 Q3 $981K
FY24 Q4 $1.1M
FY25 Q1 $977K
FY25 Q2 $726K
FY25 Q3 $22M
FY25 Q4 $46M
FY26 Q1 $72.3M
FY26 Q2 $98.9M
Revenue growth, TTM YoY Septerna, Inc.
-5000% 0% 5000% 10000% 15000% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q2: -13.4% Revenue growth, TTM YoY, FY25 Q3: 2147.2% Revenue growth, TTM YoY, FY25 Q4: 4174.5% Revenue growth, TTM YoY, FY26 Q1: 7295.6% Revenue growth, TTM YoY, FY26 Q2: 13520.1% 13520.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q2 -13.4%
FY25 Q3 2147.2%
FY25 Q4 4174.5%
FY26 Q1 7295.6%
FY26 Q2 13520.1%
Operating margin (TTM) Septerna, Inc.
-15000% -10000% -5000% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY24 Q2: -1345.8% Operating margin (TTM), FY24 Q3: -2221.0% Operating margin (TTM), FY24 Q4: -7518.4% Operating margin (TTM), FY25 Q1: -9339.1% Operating margin (TTM), FY25 Q2: -14071.1% Operating margin (TTM), FY25 Q3: -349.2% Operating margin (TTM), FY25 Q4: -148.6% Operating margin (TTM), FY26 Q1: -77.1% Operating margin (TTM), FY26 Q2: -44.0% -44.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -1345.8%
FY24 Q3 -2221.0%
FY24 Q4 -7518.4%
FY25 Q1 -9339.1%
FY25 Q2 -14071.1%
FY25 Q3 -349.2%
FY25 Q4 -148.6%
FY26 Q1 -77.1%
FY26 Q2 -44.0%
FCF margin (TTM) Septerna, Inc.
-15000% -10000% -5000% 0% 5000% FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 FCF margin (TTM), FY24 Q3: -5916.3% FCF margin (TTM), FY24 Q4: -6471.9% FCF margin (TTM), FY25 Q1: -7760.8% FCF margin (TTM), FY25 Q2: -11436.9% FCF margin (TTM), FY25 Q3: 467.9% FCF margin (TTM), FY25 Q4: 238.7% FCF margin (TTM), FY26 Q1: 148.0% FCF margin (TTM), FY26 Q2: 106.3% 106.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q3 -5916.3%
FY24 Q4 -6471.9%
FY25 Q1 -7760.8%
FY25 Q2 -11436.9%
FY25 Q3 467.9%
FY25 Q4 238.7%
FY26 Q1 148.0%
FY26 Q2 106.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 46 99
EBITDA 3 −79 −67 −42
Operating income 2 −81 −68 −44
Net income 4 −72 −49 −24
Diluted EPS $0.29 −$7.26 −$1.10 −$0.54
Growth (year on year)
Revenue — +611.9% +>999% +>999%
EBITDA — <−999% — —
Operating income — <−999% — —
Net income — <−999% — —
Diluted EPS — <−999% — —
Margins
EBITDA margin >999% <−999% −145.1% −42.4%
Operating margin >999% <−999% −148.6% −44.0%
Net margin >999% <−999% −106.4% −24.5%
Free-cash-flow margin <−999% <−999% 238.7% 106.3%
Cash flow
Cash from operations −39 −67 110 106
Capital spending 3 2 1 1
Free cash flow −42 −70 110 105
Stock-based pay 2 3 8 16
Free cash flow after stock pay −43 −73 101 89
Balance sheet
Cash 88 238 121 85
Total debt 0 0 0 0
Net debt (negative = net cash) −88 −238 −121 −85
Diluted shares 2m 10m 44m 45m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $567m
Short-term assets $396mLonger-term assets $171m
What it owes, and who funded it · $567m
Short-term liabilities $79mLonger-term liabilities $101mShareholders' equity $387m
  • Short-term assets cover short-term liabilities $396m of assets due within a year against $79m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $396m short-term assets against $101m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Septerna, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
122.2%
of revenue
Days sales outstanding
45 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated SEPN AGIO KYMR XNCR FDMT VSTM Median
Revenue, last 12 months $99m $98m $102m $105m $92m $88m $56m
Revenue growth, last 12 months >999% 140.6% 133.8% −28.6% >999% 26.4% 12.6%
Revenue growth, 3-year average — 69.6% 29.7% −2.5% 242.8% 58.4% 13.7%
Revenue growth, latest quarter >999% 259.3% −100.0% 17.5% >999% >999% 10.2%
Gross margin — 92.0% 0.0% — — — 82.9%
Operating margin −44.0% −466.8% −396.0% −205.8% −214.2% −182.6% −189.4%
Operating margin, 3-year average <−999% −963.3% −461.5% −136.0% <−999% −813.6% −363.5%
Net margin −24.5% −418.2% −341.8% −155.6% −194.7% −231.6% −169.8%
Cash from operations / revenue 107.2% −366.7% −281.3% −196.1% −169.6% −185.3% −168.0%
Free-cash-flow margin 106.3% −371.4% −282.6% −198.4% −169.6% −185.3% −162.4%
Free-cash-flow margin, 3-year average — −784.8% −326.1% −128.0% <−999% — −310.0%
Stock pay / revenue 16.5% 59.0% 66.7% 37.2% 22.2% 11.1% 20.0%
Change in share count — 0.4% 17.6% 5.2% 15.9% 33.4% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 13520.1% 12.6% 3 of 172
Change in growth rate Growth +6224.5pp -0.1pp 2 of 172
Operating margin Profitability -44.0% -189.4% 61 of 175
Net margin Profitability -24.5% -157.3% 52 of 180
Free-cash-flow margin Cash generation 106.3% -145.4% 1 of 176
Stock pay as % of revenue Cash generation 16.5% 19.2% 82 of 179
Days sales outstanding Balance sheet 45 days 75 days 23 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$1.6B
Institutions reporting
154
Shares held vs prior quarter
▲ 3.3%
Positions opened / closed
46 / 16

Top buyers and sellers, Q2 2026: 95 institutions bought and 48 sold ; the biggest buyer was Loomis Sayles & Co L P (+625K shares) and the biggest seller Bvf Inc (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $234M 7.0M 14.7% 0.0%
Trv Gp V, LLC $208M 6.2M 13.1% 0.0%
Driehaus Capital Management LLC $148M 4.4M 9.3% ▲ 0.9%
Trv Gp Vi, LLC $141M 4.2M 8.9% 0.0%
Samsara Biocapital, LLC $105M 3.1M 6.6% 0.0%
Goldman Sachs Group Inc $103M 3.1M 6.5% ▲ 5.4%
Blackrock, Inc. $64.7M 1.9M 4.1% ▲ 6.0%
Siren, L.L.C. $63.6M 1.9M 4.0% ▼ 5.0%
Avoro Capital Advisors LLC $44.8M 1.3M 2.8% 0.0%
Jupiter Topco LLC $43.7M 1.3M 2.8% —
Vanguard Capital Management LLC $40.9M 1.2M 2.6% ▲ 2.1%
Primecap Management Co $39.1M 1.2M 2.5% ▲ 11.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Septerna, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $44.5M 28 trades by 5 insiders · 29% under pre-set plans
Net ▼ $44.5M net selling
Insider Date Trade Shares Price Value
Bhatt Elizabeth President and COO October 15, 2026 Sell pre-set plan 2,906 $37.61 $109,307
Bhatt Elizabeth President and COO October 15, 2026 Sell pre-set plan 1,094 $36.87 $40,337
Long Daniel D. SVP, Drug Discovery September 1, 2026 Sell pre-set plan 3,333 $37.83 $126,087
Shah Rajeev M. Director August 12, 2026 Sell 746,500 $42.50 $31.7M
Third Rock Ventures Gp Vi, L.P. 10% owner August 12, 2026 Sell pre-set plan 147,059 $50.27 $7.4M
Third Rock Ventures Gp Vi, L.P. 10% owner August 12, 2026 Sell pre-set plan 141 $51.08 $7,202
Bhatt Elizabeth President and COO August 11, 2026 Sell pre-set plan 25,000 $44.00 $1.1M
Long Daniel D. SVP, Drug Discovery August 3, 2026 Sell pre-set plan 1,000 $33.98 $33,980
Long Daniel D. SVP, Drug Discovery August 3, 2026 Sell pre-set plan 2,334 $34.68 $80,943
Bhatt Elizabeth President and COO July 15, 2026 Sell pre-set plan 4,000 $33.99 $135,960
Long Daniel D. SVP, Drug Discovery July 1, 2026 Sell pre-set plan 2,100 $34.10 $71,610
Long Daniel D. SVP, Drug Discovery July 1, 2026 Sell pre-set plan 1,233 $34.81 $42,921

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 11, 2026
  • March 9, 2026
  • November 10, 2025
  • August 11, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on Septerna, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Septerna, Inc. in brief

What does Septerna, Inc. do?
Septerna, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Septerna, Inc.'s stock ticker?
Septerna, Inc. trades under the ticker SEPN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Septerna, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Septerna, Inc. reported revenue of $98.9M, 13520.1% higher than a year earlier, according to its SEC filings.
What is Septerna, Inc.'s free cash flow?
Septerna, Inc.'s free-cash-flow margin is 106.3% of revenue over the trailing twelve months, ranking 1 of the 176 biotechnology companies we cover.
What is Septerna, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Septerna, Inc.'s free cash flow after stock-based pay gives ~$26 per share in the base case, and ~$22–$32 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Septerna, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Trv Gp V, LLC and Driehaus Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Septerna, Inc.'s market cap?
On November 2, 2026, Septerna, Inc.'s market capitalisation was about $1.9B and net debt of -$84.7M. Market figures come from third-party market data and may be delayed.
Who are Septerna, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Septerna, Inc. are Agios Pharmaceuticals, Inc., Kymera Therapeutics, Inc., Xencor Inc, 4d Molecular Therapeutics, Inc. and Verastem, Inc. The side-by-side comparison below sets their revenue, margins and growth against Septerna, Inc.'s.
Are insiders buying or selling Septerna, Inc. stock?
Over the last 12 months, Septerna, Inc.'s directors and officers reported 0 open-market purchases and 28 sales on Form 4. The insider trading page charts every trade.
When is Septerna, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Septerna, Inc. announces its own schedule.